Uptake of breast cancer prevention and screening trials

Journal of Medical Genetics

Volumn 47, Issue 12, 2010, Pages 853-855

  Evans, D Gareth ^a,b   Harvie, Michelle ^a   Bundred, Nigel ^a   Howell, Anthony ^a,b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; GOSERELIN; PLACEBO; RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL RESEARCH; CLINICAL TRIAL; HIGH RISK POPULATION; HUMAN; MAMMOGRAPHY; PRIORITY JOURNAL; WEIGHT REDUCTION;

BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 78649630549     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmg.2010.082768     Document Type: Article

References (15)

1. NCRN/NIHR Breast trials recruitment. http://ncrndev.org.uk/downloads/csg/ 2009/ Breast%20CSG%202008-09%20rep.final.pdf.
2. Evans DGR, Lalloo F, Shenton A, Boggis C, Howell A. Uptake of screening and prevention trials in women at very high risk of breast cancer. Lancet 2001;358:889-90. (Pubitemid 32900574)
3. Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003;40:807-14.
4. Harvie M, Cohen H, Mason C, Mercer T, Malik R, Adams J, Evans DGR, Hopwood P, Cuzick J, Howell A. Adherence to a diet and exercise weight loss intervention amongst women at increased risk of breast cancer. The Open Obesity Journal (Bentham) pp.71-80(10) 2010.
5. Harvie M, Chapman M, Cuzick J, Flyvbjerg A, Hopwood P, Jebb S, Parfitt G, Howell A. The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women. International Journal of Obesity. In press.
6. Evans DG, Lalloo F, Ashcroft L, Shenton A, Clancy T, Baildam AD, Brain A, Hopwood P, Howell A. Uptake of risk reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age and time dependent. Cancer Epid Biomarkers Prev 2009;18:2318-24.
7. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N. National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
8. Senior K. COX-2 inhibitors: cancer prevention or cardiovascular risk? Lancet Oncol 2005;6:68.
9. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27. (Pubitemid 36999703)
10. Edwards AG, Evans R, Dundon J, Haigh S, Hood K, Elwyn GJ. Personalised risk communication for informed decision making about taking screening tests. Cochrane Database Syst Rev 2006;(4):CD001865.
11. Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, Knight R, Entwistle V, Garcia J, Roberts I, Grant A, Grant A; STEPS group. Recruitment to randomised trials: strategies for trial enrollment and participation study. The STEPS study. Health Technol Assess 2007;11:iii, ix-105.
12. Ulrich CM, James JL, Walker EM, Stine SH, Gore E, Prestidge B, Michalski J, Gwede CK, Chamberlain R, Bruner DW. RTOG physician and research associate attitudes, beliefs and practices regarding clinical trials: implications for improving patient recruitment. Contemp Clin Trials 2010;31:221-8.
13. Donovan JL, Lane JA, Peters TJ, Brindle L, Salter E, Gillatt D, Powell P, Bollina P, Neal DE, Hamdy FC; ProtecT Study Group. Collaborators (19) Bonnington S, Cooper D, Doble A, Doherty A, Elliott E, Herbert P, Holding P, Howson J, Jones M, Kockelbergh R, Kynaston H, Lennon T, Lyons N, Moody H, Prescott S, Thompson P, Toerien M, Tomlin Z, de Salis I. Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. J Clin Epidemiol 2009;62:29-36.
14. Waters EA, Cronin KA, Graubard BI, Han PK, Freedman AN. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 2010;19:443-6.
15. Metcalfe KA, Ghadirian P, Rosen B, Foulkes W, Kim-Sing C, Eisen A, Ainsworth P, Horsman D, Maugard C, Provencher D, Robideaux A, Gilchrist D, Chudley A, Lemire EG, Armel S, Finch A, Sun P, Narod SA. Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Open Med 2007;1:e92-8.